{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:54:59Z","timestamp":1784580899345,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202089"],"award-info":[{"award-number":["7202089"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81690264"],"award-info":[{"award-number":["81690264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2018ZX09721003-004"],"award-info":[{"award-number":["2018ZX09721003-004"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jconrel.2021.08.058","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:14:29Z","timestamp":1630494869000},"page":"462-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Engineering a \u201cthree-in-one\u201d hirudin prodrug to reduce bleeding risk: A proof-of-concept study"],"prefix":"10.1016","volume":"338","author":[{"given":"Yuanjun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu-Hu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liandi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.08.058_bb0005","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0010","series-title":"StatPearls, Treasure Island (FL)","article-title":"Thrombosis","author":"Ashorobi","year":"2021"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0015","first-page":"294","article-title":"Upper gastrointestinal bleeding in adults: evaluation and management","volume":"101","author":"Wilkins","year":"2020","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0020","first-page":"66","article-title":"Balancing ischaemia and bleeding risks with novel oral anticoagulants","volume":"12","author":"Baber","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0025","article-title":"A practical review of the emerging direct anticoagulants, laboratory monitoring, and reversal agents","volume":"7","author":"Joppa","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0030","first-page":"333","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0035","first-page":"29895","article-title":"Engineering factor Xa inhibitor with multiple platelet-binding sites facilitates its platelet targeting","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0040","first-page":"253","article-title":"Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors","volume":"95","author":"Zhu","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0045","first-page":"1344","article-title":"Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium","volume":"104","author":"Chen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0050","first-page":"909","article-title":"Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases","volume":"8","author":"Kelley","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0055","first-page":"680","article-title":"Effect of fluid shear stress on the internalization of kidney-targeted delivery systems in renal tubular epithelial cells","volume":"10","author":"Xu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0060","first-page":"429","article-title":"Organisation to assess strategies for ischemic syndromes (OASIS-2) investigators","volume":"353","author":"Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0065","first-page":"1631","article-title":"The global use of strategies to open occluded coronary arteries (GUSTO) IIA investigators","volume":"90","author":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0070","first-page":"259","article-title":"Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs","volume":"69","author":"Iyer","year":"1993","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0075","first-page":"237","article-title":"Studies on the pharmacokinetics of hirudin","volume":"46","author":"Markwardt","year":"1987","journal-title":"Biomed. Biochim. Acta."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0080","first-page":"4557","article-title":"Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin","volume":"31","author":"Betz","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0085","first-page":"166","article-title":"Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics","volume":"121","author":"Dong","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0090","first-page":"237","article-title":"Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner","volume":"42","author":"Peter","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0095","first-page":"324","article-title":"Construction and functional evaluation of hirudin derivatives with low bleeding risk","volume":"99","author":"Zhang","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0100","article-title":"Self-regulated hirudin delivery for anticoagulant therapy","volume":"6","author":"Xu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0105","first-page":"1158","article-title":"Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa","volume":"101","author":"Peter","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0110","series-title":"All About Albumin: Biochemistry, Genetics, and Medical Applications","author":"Theodore Peters","year":"1995"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0115","first-page":"21","article-title":"A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss","volume":"18","author":"Sheffield","year":"2018","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0120","first-page":"2852","article-title":"Necrotic platelets provide a procoagulant surface during thrombosis","volume":"126","author":"Hua","year":"2015","journal-title":"Blood"},{"issue":"2016","key":"10.1016\/j.jconrel.2021.08.058_bb0125","article-title":"Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting","volume":"128","author":"Podoplelova","year":"1745","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0130","first-page":"15","article-title":"Procoagulant phosphatidylserine-exposing platelets in vitro and in vivo","volume":"7","author":"Reddy","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0135","first-page":"515","article-title":"Engineering of a femtomolar affinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0140","first-page":"119869","article-title":"Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug","volume":"589","author":"Han","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0145","first-page":"1903","article-title":"Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques","volume":"6","author":"Burtea","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0150","first-page":"1025","article-title":"Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer","volume":"40","author":"Richter","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0155","first-page":"461","article-title":"Modeller: generation and refinement of homology-based protein structure models","volume":"374","author":"Fiser","year":"2003","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0160","first-page":"13","article-title":"Codon usage and tRNA content in unicellular and multicellular organisms","volume":"2","author":"Ikemura","year":"1985","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0165","first-page":"907","article-title":"Mass spectrometry compatible surfactant for optimized in-gel protein digestion","volume":"85","author":"Saveliev","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0170","first-page":"17920","article-title":"Peptide toxin glacontryphan-M is present in the wings of the butterfly Hebomoia glaucippe (Linnaeus, 1758) (Lepidoptera: Pieridae)","volume":"109","author":"Bae","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0175","first-page":"407","article-title":"Experimental arterial thrombosis in rats with continuous registration","volume":"26","author":"Hladovec","year":"1971","journal-title":"Thromb. Diath. Haemorrh."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0180","first-page":"287","article-title":"Optimization of ferric chloride induced thrombosis model in rats: effect of anti-platelet and anti-coagulant drugs","volume":"61","author":"Surin","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0185","first-page":"328","article-title":"Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase","volume":"31","author":"Gao","year":"2012","journal-title":"Protein J."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2021.08.058_bb0190","first-page":"133","article-title":"Clinical pharmacology of recombinant hirudin","volume":"21","author":"Markwardt","year":"1991","journal-title":"Haemostasis"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0195","article-title":"Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0200","first-page":"297","article-title":"Mechanisms of antithrombotic drugs","volume":"46","author":"Thiagarajan","year":"1999","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0205","first-page":"315","article-title":"The major histocompatibility complex-related fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0210","first-page":"1688","article-title":"Microemulsion and bovine serum albumin nanoparticles as a novel hybrid nanocarrier system for efficient multifunctional drug delivery","volume":"108","author":"Gharbavi","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2021.08.058_bb0215","first-page":"1097","article-title":"Albiglutide: a once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus","volume":"72","author":"Davis","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.058_bb0220","first-page":"903","article-title":"Half-life extended biotherapeutics","volume":"16","author":"Kontermann","year":"2016","journal-title":"Expert. Opin. Biol. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:11:07Z","timestamp":1759162267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921004727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":44,"alternative-id":["S0168365921004727"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.058","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering a \u201cthree-in-one\u201d hirudin prodrug to reduce bleeding risk: A proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}